Position in JANX
as of Mar 31, 2026
· filed May 18, 2026
Position Value
$10,644,675
New position
Shares Held
765,804
first reported quarter
Ownership
1.26%
of shares outstanding
% of Portfolio
1.04%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Irenic Capital Management LP holds $60,349,374 across 6 Biotechnology names. JANX ranks #2 (17.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TBPH |
Theravance Biopharma, Inc.
|
2,760,948 | $44,810,186 | |
| 2 | JANX |
Janux Therapeutics, Inc.
This page
|
765,804 | $10,644,675 | |
| 3 | QURE |
uniQure N.V.
|
100,000 | $1,635,000 | |
| 4 | AVIR |
Atea Pharmaceuticals, Inc.
|
301,699 | $1,623,140 | |
| 5 | FATE |
Fate Therapeutics Inc
|
878,055 | $1,053,666 | |
| 6 | VOR |
Vor Biopharma Inc.
|
32,663 | $582,707 |
All Filings in JANX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $10,644,675 | 765,804 | Shares | Sole | 2026-05-18 | |
| No filing history on record for this holder in this stock. | ||||||